Singapore markets closed

REGENXBIO Inc. (RGNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.69-0.49 (-2.21%)
As of 12:30PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.09B
Enterprise value 900.69M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)10.75
Price/book (mrq)3.49
Enterprise value/revenue 9.98
Enterprise value/EBITDA -3.76

Trading information

Stock price history

Beta (5Y monthly) 1.27
52-week change 322.68%
S&P500 52-week change 329.57%
52-week high 328.80
52-week low 311.83
50-day moving average 318.12
200-day moving average 317.96

Share statistics

Avg vol (3-month) 3801.2k
Avg vol (10-day) 3600.71k
Shares outstanding 548.99M
Implied shares outstanding 648.99M
Float 837.26M
% held by insiders 17.43%
% held by institutions 182.62%
Shares short (15 Mar 2024) 44.15M
Short ratio (15 Mar 2024) 43.89
Short % of float (15 Mar 2024) 410.64%
Short % of shares outstanding (15 Mar 2024) 48.47%
Shares short (prior month 15 Feb 2024) 44.17M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -291.99%
Operating margin (ttm)-271.03%

Management effectiveness

Return on assets (ttm)-23.49%
Return on equity (ttm)-63.65%

Income statement

Revenue (ttm)90.24M
Revenue per share (ttm)2.06
Quarterly revenue growth (yoy)-29.10%
Gross profit (ttm)N/A
EBITDA -247.11M
Net income avi to common (ttm)-263.49M
Diluted EPS (ttm)-6.02
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)275.26M
Total cash per share (mrq)6.2
Total debt (mrq)183.34M
Total debt/equity (mrq)58.81%
Current ratio (mrq)2.57
Book value per share (mrq)7.08

Cash flow statement

Operating cash flow (ttm)-218.41M
Levered free cash flow (ttm)-133.51M